Medpace stock reports 17.20 percent Q2 revenue growth

Published on 09/30/2026 at 09:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Medpace stock posted USD 4.25 diluted EPS against USD 3.98 consensus in Q2 2026. Fiscal 2026 EPS guidance stands at USD 17.25-17.95, while Jefferies rates Hold at USD 560.00.

MEDP, US5840631062, Illustration mit AI erstellt.

Medpace (ISIN US5840631062) delivered USD 707.30 million in second-quarter 2026 revenue, an increase of 17.20 percent from the prior-year period. The clinical research organization also reported diluted EPS of USD 4.25 against consensus of USD 3.98, keeping earnings growth at the center of the investment case.

Q2 revenue clears USD 700 million

According to Business Wire, Medpace's revenue for the three months ended June 30, 2026 rose from USD 603.30 million in the comparable period. The USD 104.00 million increase shows that demand for outsourced clinical development services remained a measurable growth driver.

The company reported net income attributable to common shareholders of USD 121.36 million for Q2 2026, while operating profit reached USD 146.82 million. Operating cash flow was USD 162.01 million in the same quarter, giving the result a cash conversion component beyond the earnings headline.

Guidance sets the next checkpoint

Medpace guided to fiscal 2026 EPS of USD 17.25-17.95, according to MarketBeat. The range places the quarterly USD 4.25 diluted EPS result against a full-year outlook that implies continued earnings delivery across the remaining reporting periods.

The next scheduled report is October 21, 2026, after the market close, with a conference call on October 22, 2026, at 9:00 a.m. ET, per Business Wire. That date gives investors a defined point for testing the guidance range against fresh bookings, revenue and margin data.

Jefferies keeps a Hold view

On September 14, 2026, Jefferies reiterated a Hold rating and a USD 560.00 price target, as reported by Investing.com. The cautious stance contrasts with the Q2 revenue increase and reflects the need to weigh present growth against future study timing and operating leverage.

Medpace's chief executive August J. Troendle sold 70,901 shares in transactions dated September 21 and September 22, 2026, totaling USD 44.40 million, according to Investing.com. The filing-related sales add a concrete insider transaction to the earnings and valuation discussion.

TradeGate quote dated September 8

The last dated TradeGate quote was EUR 505.20 on September 8, 2026. On the Nasdaq, MEDP was quoted at USD 622.11 on September 29, 2026 at 4:00 p.m. ET, with a market capitalization of USD 17.4 billion and a 52-week range of USD 373.00 to USD 677.90.